Media Articles Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
Long-Term Pain Outcomes With DBS in Parkinson's
Source: Medscape NeurologyHeadlines [2015.04.10]
Overall, pain improved in patients with Parkinson's 8 years after having deep brain stimulation, but new pain, mostly musculoskeletal, developed.
Medscape Medical News
MOVANTIK (naloxegol) tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain launched in the US
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.04.10]
AstraZeneca has announced that MOVANTIK (naloxegol) has launched in the United States.
Combining morphine and nortriptyline relieves chronic neuropathic pain better than using either drug alone
Source: Neurology / Neuroscience News From Medical News Today [2015.04.10]
Combining nortriptyline and morphine provides better pain relief than using either drug alone, according to a new study led by Queen's researcher Ian GilronThe combination of two well-known drugs...
Enhancing mechanism of capsaicin-evoked pain sensation
Source: Pain / Anesthetics News From Medical News Today [2015.04.09]
Calcium influx through TRPV1 causes anoctamin 1 activationDrs. Takayama and Tominaga in National Institute for Physiological Sciences (NIPS) (Okazaki Institute for Integrative Bioscience)...
Shift From IV to Oral Sedation for Pain Procedures?
Source: Medscape Emergency Medicine Headlines [2015.04.08]
One pain center reports benefits from a policy shifting from intravenous sedation to oral anxiolysis, but some argue IV sedation is often important.
Medscape Medical News
Published Studies Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. 
BACKGROUND/AIMS: To evaluate the benefit of adding a nonsteroid agent to an antibiotic/steroid combination after uneventful phacoemulsification, adopting a weekly follow-up, to gain insight into the optimal duration of postoperative treatment and to examine whether risk factors for inflammation exist... CONCLUSION: The addition of ketorolac did not seem to offer any additional benefit in terms of inflammation-related signs. Four weeks appeared as an adequate treatment interval. Special attention should be paid to patients with pseudoexfoliation. Copyright (c) 2010 S. Karger AG, Basel.
Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. [2010.12]
OBJECTIVE: To determine the level of intraocular penetration of diclofenac sodium and ketorolac tromethamine into the aqueous humour and subretinal fluid. DESIGN: Prospective randomized clinical trial. PARTICIPANTS: Twenty eyes scheduled for retinal detachment surgery and 17 eyes scheduled for cataract surgery... CONCLUSIONS: The concentration in the subretinal fluid of topically applied diclofenac was higher than that of ketorolac; and topical ketorolac penetrated into the aqueous humour better than diclofenac did. This suggests that diclofenac can be used more effectively in events related to posterior segment and ketorolac in anterior segment events.
Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery. [2010.05]
PURPOSE: To compare the anti-inflammatory efficacy and subjective tolerability of preservative-free and preserved diclofenac 0.1% and preserved ketorolac 0.5% eye drops for prophylaxis and management of inflammation after cataract surgery. DESIGN: Prospective, randomized, investigator-masked, parallel-group, comparative clinical trial... CONCLUSIONS: Anti-inflammatory efficacy was comparable for all 3 agents. However, preservative-free diclofenac 0.1% eyedrops exhibited a significantly better postoperative subjective and objective tolerability when compared with preserved eyedrops containing ketorolac or diclofenac. Copyright 2010 Elsevier Inc. All rights reserved.
Use of Acular LS in the pain management of keratoconus: a pilot study. [2010.02]
PURPOSE: The purpose of this pilot study was to determine the efficacy of ketorolac tromethamine 0.4% for pain management in conjunction with rigid gas permeable contact lenses in keratoconus. Any potential side effects and complications of this application were examined... CONCLUSIONS: There was no conclusive result as to the efficacy of the ketorolac tromethamine 0.4% vs. the artificial tear solution in the pain management of keratoconus. This could be attributed to a number of physiological and situational factors, as well as small sample size.
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]
INTRODUCTION: Ketorolac 0.4% administered four times daily (q.i.d.) has long been used safely and effectively for the alleviation of ocular inflamation and pain and the prevention of intraoperative miosis in patients undergoing cataract surgery. Bromfenac ophthalmic solution 0.09% was recently developed as an ocular anti-inflammatory drug with a twice-daily (b.i.d.) dosing regimen. This study was designed to evaluate if b.i.d. dosing with bromfenac 0.09%, in comparison with q.i.d. dosing with ketorolac 0.4%, provides adequate trough nonsteroidal anti-inflammatory drug levels that were effective enough to reduce aqueous prostaglandin (PG) E(2) levels of patients after cataract surgery toward the end of its dosing cycle... CONCLUSIONS: Ketorolac 0.4% maintained significantly higher aqueous concentrations and lowered aqueous PGE(2) levels significantly more than bromfenac 0.09% at trough levels. Ketorolac 0.4% administered q.i.d. may provide a more sustained control of intraocular inflammation and pain than bromfenac 0.09% administered b.i.d.
Clinical Trials Related to Acular PF (Ketorolac Tromethamine Ophthalmic)
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity [Enrolling by invitation]
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye
drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or
decrease its severity. In this study ACULAR will be compared to a placebo (artificial tear).
The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to
severe ROP (grade II and above)by 50%.
An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain [Not yet recruiting]
The purpose of this study is to determine the effectiveness, the safety, and the
tolerability of intranasal ketorolac (Sprix) in relieving acute pain in adults ages 18-64
who come to the ED seeking care. Considering all ED visits, pain is the most common chief
complaint. Giving intranasal ketorolac (Sprix) after stomach and dental surgeries has been
shown to be safe and effective, but no studies have investigated the use of intranasal
ketorolac (Sprix) for the treatment of acute pain in the ED.
Ketorolac (Sprix) has several advantages over other drugs commonly given for pain, including
opioids. Ketorolac (Sprix) is non-addicting and has fewer side effects than opioids. The
administration of ketorolac (Sprix) by other methods, such as IV, intramuscular shot, and
oral pill form, has been shown to be safe and effective in treating acute pain.
This study is being done to find out if giving ketorolac (Sprix) as a single dose nasal
spray will have the same benefit in decreasing patient's pain.
Disposition of Intravenous Ketorolac [Not yet recruiting]
The purpose of this study is:
- to document ketorolac disposition (concentration/time profile, protein binding,
metabolism) and its covariates following intravenous (iv) administration of ketorolac
right after caesarean section and to compare those observations (n=32) with
non-pregnant state (n=8) (intra-subject PK comparison)
- to document biochemical tolerance of ketorolac
- to evaluate if optimalisation of ketorolac dose regimen during pregnancy and labor are
appropriated and needed
- to quantify the neonatal exposure to ketorolac through excretion in the breast milk
Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement [Recruiting]
Intrauterine device (IUD) placement can be painful for patients during and after the
procedure. Fear of pain from IUD insertion can be a barrier to obtaining this highly
effective long acting reversible contraception. Currently there are no proven effective
methods for reduction of pain during and after placement of modern IUDs (Mirena IUD and
Paragard IUD). Ketorolac has not been studied in regards to decreasing pain during and after
IUD insertion although it is used by some providers for this purpose. It is a strong NSAID
that is indicated for the treatment of moderate acute pain. In the intramuscular form it has
an analgesia onset of action at 30min, thus may be a plausible option for pain management in
the office setting compared to oral NSAIDs, which have a longer time to onset of analgesia
and have not been proven to be effective in reducing pain associated with IUD placement. The
primary aim of this study is to determine whether ketorolac (Toradol) decreases pain
associated with intrauterine device placement compared to placebo. We hypothesize that
administration of ketorolac 30mg intramuscularly at least 30 minutes prior to IUD insertion
will decrease pain scores by at least 20mm on a visual analog scale at various time points
during IUD insertion when compared to placebo of normal saline injection.
Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery [Completed]
This study evaluates the safety and efficacy of ketorolac for post-operative pain management
after heart surgery. Ketorolac appears to provide enhanced pain relief while also decreasing
the requirements for morphine during the (immediate) 24-hour post-operative period.